Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Vasculitis 1Urogenital Neoplasms 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Pemphigoid, Benign Mucous Membrane 1Melanoma 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Granulomatous Disease, Chronic 1Cytokine Release Syndrome 1Crohn Disease 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Aneurysm 1

Interventions

otelixizumab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cytokine Release Syndrome × Infliximab × Clear all
NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡